Compliance
This section focuses on health care compliance and regulations – both national and state – including the ACA. It includes changes in health care law, regulation, and court decisions and their impact on health insurance professionals, employers, and individuals.
In a speech this week, Gottlieb suggested that the federal government should “re-examine” how rebates are treated under federal antikickback laws. Right now, those rebates don’t count as kickbacks.
Some Republican lawmakers continue to try to work around the federal health law’s requirements. That strategy can crop up in surprising places. Like the farm bill.
Health and Human Services Secretary Alex Azar said the administration is working on a plan to tackle high drug prices that would go “much further” than the proposals in President Trump’s budget.
Finance execs at the big payers all say the Medicare Advantage market will only get bigger, and more lucrative.
Health insurers are seeking lofty rate hikes for 2019 individual coverage as they grapple with new obstacles in the Affordable Care Act marketplace, including the zeroed-out mandate penalty and the potential influx of skimpy insurance policies.
Aetna, Humana and UnitedHealthcare all reported positive financial results this quarter and executives cited the same reason: swelling numbers of Medicare Advantage enrollees, otherwise known as the Silver Tsunami.
Health and Human Services Secretary Alex Azar said the administration is working on a plan to tackle high drug prices that would go “much further” than the proposals in President Trump’s budget.
Health insurers are seeking lofty rate hikes for 2019 individual coverage as they grapple with new obstacles in the Affordable Care Act marketplace, including the zeroed-out mandate penalty and the potential influx of skimpy insurance policies.
Some Republican lawmakers continue to try to work around the federal health law’s requirements. That strategy can crop up in surprising places. Like the farm bill.
The coupons typically offer patients with commercial insurance a break on their copayment for brand-name drugs, often reducing their out-of-pocket costs to what they would pay for inexpensive generic drugs.